Member Info for Basser1

You are very good at your job but speak with a forked tongue. Hope your employer is paying you well. Personally I do not trust anything you say. You are as false as your pal who tried to defend so called abuse against certain posters -which turned out all to be a sham. Glad I was lucky never to have a job like you have. Goodbye.

As has been said on numerous occasions, Covid is a side play for Sareum.
The comments on valuations are based on longer term developments in Autoimmune and Cancer treatments. If you are in a rush, and invested simply because of Covid 19 then think that you should sell, The potential of SRA737, SDc1801 and SDC1802 is compelling. That’s why many here are sitting on their hands. As WB famously said ‘ The Stock Market is a device for transferring money from the impatient to the patient’.
Are you impatient or patient?

Quote from prospectus
‘’Our principal sources of liquidity as of September 30, 2021 were cash and cash equivalents of $97.1 million. Given our projected operating requirements and our existing cash and cash equivalents, we have projected insufficient liquidity to fund our operations for the next twelve months beyond the date of the issuance of the condensed consolidated financial statements included in the Quarterly Report on Form 10-Q for September 30, 2021, which raises substantial doubt about our ability to continue as a going concern. To fund our operating plans and remain as a going concern, we intend to seek additional funds through equity or debt financings, collaborations, licensing transactions or other sources.’’
Seems likely to me that SRA 737 will not be kept solely in house and that the ‘’Optimal Development Plan” for SRA 737 will include a number of opportunities to try combination therapies in partnership or under license with other pharmaceutical companies. Bring on the Combos!

SRA 737 Now firmly back in Sierra’s Portfolio. With all the scientific evidence published over the last two years supporting SRA 737 in combination studies, I would expect the Prospectus offer of 200,000,000 dollars to be over subscribed.

Our portfolio also includes SRA737, a selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), an emerging target for the treatment of cancer which has a key role in the DNA Damage Response (DDR). In November 2020, we entered into an amendment to the License Agreement with CRT Pioneer Fund (CPF) to allow for the potential future clinical development of SRA737. We continue to evaluate the optimal development plan for SRA737 in solid tumors and may initiate new trials for SRA737 in 2022.

https://quantisnow.com/insight/1967028?s=s

Just catching up. Anyone seen this?

Warthog - I’m not so sure but if you are right there’s always viral pneumonia, sepsis and 39 autoimmune conditions!!.

Noted the interest in potential treatment of long covid. Makes sense really as SDC1801 is all about dampening down our own immune systems which thru over reaction, cause so much of the illnesses we can suffer from - and there are very many auto immune indications.

Agree Gunner. SRA737 has been through Phase1 and Phase2 clinical trials. Sierra will be looking for some fast tracking in indications where there is a pressing clinical need. And the range of solid tumour cancers it can potential treat -those that have a TP 3 mutation are present in 50% of all solid tumour cancers. There are 20 solid tumour cancers in all ie all the big ones.

Tim was clear on Peel Hunt - it is the avenue to getting more institutional investors on board. I am very confident that will happen.GLA

You were found out on this subject so repeat it at your peril.

Desamax

Our analysis shows that patent approvals have a substantial and long-lasting impact on startups, especially the first time startups apply for patent protection: startups whose first patent application is approved create more jobs, enjoy faster sales growth, and are more innovative than startups with only randomly different inventions that fail to win patent protection. Thanks drama.

The mm’s are not helping- sea of blue buys and we are 5% down. Definitely a call for a stewards enquiry.

The boss has signalled a retreat for now. Tomorrow Let’s combat any further shallow and disruptive thinking thinking with lots of evidence based views.

Jimmy has set out some recorded evidence which puts Andy’s stoic support for the insulted into question for all to see. He is good at what he does though and he certainly deserves a bonus from his employer for making the last 4 pages of comments mainly drivel and a turn off. Now to ndr50n- please provide a detailed analysis for us to see about the ‘consequences of the delay”

Stach - there is a great opportunity to ask about Toxicity issues at the investors conference next Tuesday.

Do you want a clinical trial to start three months earlier with a less effective molecule rather than wait for the new formulation which could well be groundbreaking on a global scale?

The gold nugget.